Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe autoimmune diseases. Sponsored by ...

Connective tissue diseases (CTDs) associated with interstitial lung disease (ILD) involve autoimmune disorders affecting the skin, joints, and lungs, leading to inflammation and fibrosis. Conditions ...

Argenx SE ARGX stock has faced pressure after the company disclosed changes to the analysis plan for its ongoing Phase 3 Vyvgart study in myositis. However, H.C. Wainwright said they remain encouraged ...

As the actor prepares for motherhood after battling a rare autoimmune muscle disorder, top gynaecologist explains the risks, medication challenges and precautions needed for a healthy pregnancy ...

NEW findings reinforce that fatigue is not just a secondary symptom in myositis, but a central feature of disease activity that should be routinely assessed in both clinical care and research.

For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant benefits at a 30-mg dose compared with placebo, according to a study ...

For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant benefits at a 30-mg dose compared with placebo, according to a study ...

Peter Frampton, British rock star and icon shared in 2019 that he has inclusion body myositis (IBM), a muscular inflammatory disease that can impact the strength of the legs, arms, and fingers. He has ...

A systematic review of randomized clinical trials (RCTs) on idiopathic inflammatory myopathies (IIMs) found that race was not appropriately reported in nearly half of the studies. A geographic ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Polymyositis. According to GlobalData, Phase III drugs for Polymyositis does not have sufficient historical data ...